On June 11, the NMPA official website showed that the Category 1 new drug Conteltinib Granules from Shouyao Holdings have been approved for marketing as a monotherapy for patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell…
On June 11, the NMPA official website showed that the first innovative drug from Langlai Technology, Lanocopan Hydrochloride Tablets, was granted marketing approval through the priority review and approval procedure for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria…
A few days ago, Johnson & Johnson announced the acquisition of Firefly Bio for $1 billion in cash, once again thrusting Degrader-Antibody Conjugates (DACs), a promising therapeutic field, into the spotlight. DACs, also known as “next-generation ADCs,” have seen increasing…
On June 10, DualityBio announced that the coaching for its RMB-denominated shares to be listed on the STAR Market has passed the acceptance inspection by the Shanghai Regulatory Bureau. Founded in 2019, DualityBio focuses on the research and development of innovative…
On June 10, the CDE official website showed that the Category 1 new drug HS-10568 Injection has been submitted for marketing approval. Based on public information and clinical trial progress, the Insight database speculates that the submitted indication is for…
On June 10 local time, Sanofi announced the termination of the Phase III MOBILIZE study (NCT06290128) of Riliprubart in patients with refractory chronic inflammatory demyelinating polyneuropathy (CIDP). Riliprubart (SAR445088, BIVV020) is a humanized IgG4 monoclonal antibody that selectively inhibits activated…
On June 10, Laekna Therapeutics issued an announcement stating that it has entered into an exclusive license agreement with Vasque Bio, Inc. Under the terms and conditions of the license agreement, Laekna has granted Vasque Bio an exclusive worldwide license…
At the 2026 ASCO Annual Meeting, Zelgen Pharmaceuticals announced for the first time the Phase II clinical data of ZG005, a PD-1/TIGIT bispecific antibody, in combination with bevacizumab as a first-line treatment for advanced hepatocellular carcinoma (HCC). Compared with the…
On June 9, the NMPA official website showed that a new indication for Tian Guangshi’s MIL62 (generic name: Obinutuzumab β Injection) has been approved for marketing, for the treatment of primary membranous nephropathy (PMN), making it the world’s first targeted…
On June 9, the NMPA official website showed that a new indication for Henlius’ PD-1 monoclonal antibody Serplulimab has been approved for marketing — in combination with oxaliplatin and tegafur/gimeracil/oteracil for neoadjuvant treatment of resectable gastric cancer with tumor PD-L1…